

# Raymond P Perez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5952245/publications.pdf>

Version: 2024-02-01

58  
papers

2,256  
citations

304701

22  
h-index

223791

46  
g-index

58  
all docs

58  
docs citations

58  
times ranked

2987  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cellular and molecular determinants of cisplatin resistance. <i>European Journal of Cancer</i> , 1998, 34, 1535-1542.	2.8	339
2	Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute. <i>Cancer</i> , 1995, 76, 1377-1387.	4.1	161
3	Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1112-1118.	1.6	158
4	Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5358-5365.	7.0	157
5	Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. <i>Biochemical Pharmacology</i> , 1994, 47, 689-697.	4.4	104
6	Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. <i>Cancer</i> , 1993, 71, 1571-1580.	4.1	98
7	Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor $\alpha$ -targeting antibody-drug conjugate, in patients with solid tumors. <i>Cancer</i> , 2017, 123, 3080-3087.	4.1	94
8	Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 1317-1322.	0.8	85
9	Characterization of folate receptor alpha (FR $\alpha$ ) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FR $\alpha$ -targeting antibody-drug conjugate mirvetuximab soravtansine. <i>Gynecologic Oncology</i> , 2017, 147, 402-407.	1.4	73
10	Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. <i>Cancer Letters</i> , 1995, 97, 177-184.	7.2	70
11	Modulation of Cell Cycle Progression in Human Tumors: A Pharmacokinetic and Tumor Molecular Pharmacodynamic Study of Cisplatin Plus the Chk1 Inhibitor UCN-01 (NSC 638850). <i>Clinical Cancer Research</i> , 2006, 12, 7079-7085.	7.0	68
12	Docetaxel/Gemcitabine Followed by Gemcitabine and External Beam Radiotherapy in Patients With Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2005, 12, 995-1004.	1.5	67
13	Resistance to alkylating agents and cisplatin: Insights from ovarian carcinoma model systems. , 1990, 48, 19-27.		65
14	A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. <i>European Journal of Cancer</i> , 1993, 29, 395-399.	2.8	65
15	Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. <i>Cancer Letters</i> , 1996, 105, 5-14.	7.2	60
16	Extracellular Membrane Vesicles Derived from 143B Osteosarcoma Cells Contain Pro-Osteoclastogenic Cargo: A Novel Communication Mechanism in Osteosarcoma Bone Microenvironment. <i>Translational Oncology</i> , 2014, 7, 331-340.	3.7	50
17	The effects of ethidium bromide induced loss of mitochondrial DNA on mitochondrial phenotype and ultrastructure in a human leukemia T-cell line (MOLT-4 cells). <i>Toxicology and Applied Pharmacology</i> , 2004, 196, 68-79.	2.8	46
18	Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines. <i>International Journal of Cancer</i> , 1991, 48, 265-269.	5.1	45

#	ARTICLE	IF	CITATIONS
19	Unusual central nervous system toxicity in a phase I study of N1N11 diethylnorspermine in patients with advanced malignancy. <i>Investigational New Drugs</i> , 1997, 15, 227-234.	2.6	39
20	Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 728-738.	2.4	38
21	New targets and challenges in the molecular therapeutics of cancer. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 5-14.	2.4	33
22	Relationship between heat shock protein 60 (HSP60) mRNA expression and resistance to platinum analogues in human ovarian and bladder carcinoma cell lines. <i>Cancer Letters</i> , 1997, 119, 63-70.	7.2	24
23	Effect of glutathione depletion on the cytotoxicity of cisplatin and iproplatin in a human melanoma cell line. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 38-44.	2.3	24
24	Primary lung mucoepidermoid carcinoma: analysis of prognostic factors using surveillance, epidemiology and end results program. <i>Clinical Respiratory Journal</i> , 2017, 11, 847-853.	1.6	24
25	In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 29, 430-434.	2.3	22
26	Soft tissue sarcomas in adults. <i>Ca-A Cancer Journal for Clinicians</i> , 1994, 44, 200-210.	329.8	20
27	Antierthrocyte autoantibody formation after therapy with interleukin-2 and gamma-interferon. <i>Cancer</i> , 1991, 67, 2512-2517.	4.1	18
28	Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. <i>Journal of Clinical Oncology</i> , 2018, 36, 617-623.	1.6	18
29	Potential of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calmodulin inhibitor. <i>Gynecologic Oncology</i> , 1992, 46, 82-87.	1.4	16
30	Pharmacokinetics and Pharmacodynamics of Mesna-Mediated Plasma Cysteine Depletion. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 1324-1328.	2.0	15
31	Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel. <i>Clinical Cancer Research</i> , 2007, 13, 3293-3301.	7.0	14
32	Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 3483-3483.	1.4	14
33	Phase I study of IMGN853, a folate receptor alpha (FR $\alpha$ )-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 5558-5558.	1.6	12
34	Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines. <i>Biochemical Pharmacology</i> , 1996, 52, 21-27.	4.4	11
35	Sponsors' and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials. <i>Clinical Trials</i> , 2017, 14, 225-233.	1.6	11
36	Detection of EWS-WTT fusion mRNA in ascites of a patient with desmoplastic small round cell tumor by RT-PCR. <i>Human Pathology</i> , 1999, 30, 239-242.	2.0	9

#	ARTICLE	IF	CITATIONS
37	The clinical development of paclitaxel and the paclitaxel/carboplatin combination. <i>European Journal of Cancer</i> , 1998, 34, 1543-1548.	2.8	8
38	Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 465-474.	2.3	8
39	Sublethal concentrations of gemcitabine (2',2'-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxPC-3 human pancreatic carcinoma cells. <i>Human and Experimental Toxicology</i> , 2007, 26, 911-921.	2.2	8
40	<i>TP53</i> Gene and Cancer Resistance in Elephants. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1789.	7.4	8
41	Phase II study of amonafide in advanced and recurrent sarcoma patients. <i>Investigational New Drugs</i> , 1992, 10, 99-101.	2.6	7
42	Preliminary single agent activity of IMGN853, a folate receptor alpha (FR $\alpha$ )-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5518-5518.	1.6	7
43	Clinical Trial Electronic Portals for Expedited Safety Reporting: Recommendations from the Clinical Trials Transformation Initiative Investigational New Drug Safety Advancement Project. <i>JMIR Cancer</i> , 2016, 2, e16.	2.4	7
44	A phase 1b, open-label, non-randomized multicenter study of birinapant in combination with conatumumab in subjects with relapsed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5571-5571.	1.6	6
45	Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics. <i>Translational Lung Cancer Research</i> , 2017, 6, 600-610.	2.8	5
46	Determinants of Cisplatin Sensitivity in Normal versus Spontaneously Transformed Rat Ovarian Surface Epithelial Cells. <i>Gynecologic Oncology</i> , 1995, 58, 312-318.	1.4	4
47	The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1291-1302.	2.4	3
48	Abstract OT2-6-03: A single arm, preoperative, pilot study to evaluate the safety and biological effects of orally administered reparixin in early breast cancer patients who are candidates for surgery. , 2013, , .		3
49	Abstract P6-03-01: A phase 1b study of the CXCR1/2 inhibitor reparixin in combination with weekly paclitaxel in metastatic HER2 negative breast cancer " First analysis. , 2015, , .		3
50	RT-PCR Quantitation of HSP60 mRNA Expression. , 2001, 39, 439-447.		2
51	Systematic analysis of design and stratification for phase III trials in first-line advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2016, 7, 66-71.	1.9	2
52	Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00519.	2.4	2
53	Irinotecan (Iri) and buparlisib (B) in previously treated patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 655-655.	1.6	2
54	Infrequent chemoradiation-induced acute esophagitis in the Asian population: A meta-analysis of published clinical trials for unresectable stage III non-small cell lung cancer. <i>Thoracic Cancer</i> , 2014, 5, 565-569.	1.9	1

#	ARTICLE	IF	CITATIONS
55	Phase 1 study assessing dovitinib (TKI258) on the pharmacokinetics of caffeine, diclofenac, omeprazole, and midazolam in patients with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, 2581-2581.	1.6	1
56	Findings from the Clinical Trials Transformation Initiative IND Safety Reporting Advancement Project.. Journal of Clinical Oncology, 2015, 33, e17636-e17636.	1.6	1
57	Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemotherapy and Pharmacology, 1995, 36, 271-278.	2.3	1
58	Ethnic difference in chemoradiation-induced esophagitis in unresectable stage III non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, e18518-e18518.	1.6	0